XRTX vs. XBIO, ATXI, HOTH, ADXS, VCNX, AIMD, SONN, FWBI, PXMD, and KZIA
Should you be buying Xyratex stock or one of its competitors? The main competitors of Xyratex include Xenetic Biosciences (XBIO), Avenue Therapeutics (ATXI), Hoth Therapeutics (HOTH), Ayala Pharmaceuticals (ADXS), Vaccinex (VCNX), Ainos (AIMD), Sonnet BioTherapeutics (SONN), First Wave BioPharma (FWBI), PaxMedica (PXMD), and Kazia Therapeutics (KZIA). These companies are all part of the "pharmaceutical preparations" industry.
Xenetic Biosciences (NASDAQ:XBIO) and Xyratex (NASDAQ:XRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
Xyratex has a net margin of 0.00% compared to Xyratex's net margin of -162.84%. Xyratex's return on equity of -36.43% beat Xenetic Biosciences' return on equity.
15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 0.2% of Xyratex shares are held by institutional investors. 9.0% of Xenetic Biosciences shares are held by company insiders. Comparatively, 6.9% of Xyratex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Xenetic Biosciences has a beta of 2.6, meaning that its share price is 160% more volatile than the S&P 500. Comparatively, Xyratex has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Xyratex has lower revenue, but higher earnings than Xenetic Biosciences. Xyratex is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Xyratex had 1 more articles in the media than Xenetic Biosciences. MarketBeat recorded 3 mentions for Xyratex and 2 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.00 beat Xyratex's score of -1.00 indicating that Xyratex is being referred to more favorably in the news media.
Xenetic Biosciences received 18 more outperform votes than Xyratex when rated by MarketBeat users. Likewise, 68.24% of users gave Xenetic Biosciences an outperform vote while only 63.41% of users gave Xyratex an outperform vote.
Xyratex has a consensus price target of $14.00, suggesting a potential upside of 377.82%. Given Xenetic Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Xyratex is more favorable than Xenetic Biosciences.
Summary
Xenetic Biosciences beats Xyratex on 9 of the 17 factors compared between the two stocks.
Get Xyratex News Delivered to You Automatically
Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
